WO2025241018 - BIOINSPIRED PEPTIDE AND USE FOR THE TREATMENT OF PERIORBITAL HYPERPIGMENTATION (DARK CIRCLES)
National phase entry is expected:
Publication Number
WO/2025/241018
Publication Date
27.11.2025
International Application No.
PCT/BR2025/050186
International Filing Date
16.05.2025
Title **
[English]
BIOINSPIRED PEPTIDE AND USE FOR THE TREATMENT OF PERIORBITAL HYPERPIGMENTATION (DARK CIRCLES)
[French]
PEPTIDE BIOINSPIRÉ ET UTILISATION POUR LE TRAITEMENT DE L'HYPERPIGMENTATION PÉRIORBITAIRE (CERNES SOMBRES)
Applicants **
BIOINTECH BIOTECNOLOGIA
Inventors
MORTARI, Márcia Renata
RAMALHO, João Daivison Silva
BOSCOLO, Samantha Galo
DE SOUZA, Adolfo Carlos Barros
MARQUES, Francisca Valéria Bezerra Sampaio
Priority Data
1020240101138
21.05.2024
BR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
INPI
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1958 | |
| EPO | Filing, Examination, Granting | 11551 | |
| Japan | Filing, Examination, Granting | 1907 | |
| South Korea | Filing, Examination, Granting | 1603 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
22,959
Contact Us
Abstract[English]
The disclosure is a peptide (Iaká (SEQ ID No1) with lightening action for periorbital hyperpigmentation, cosmetic or dermopharmaceutic composition containing this peptide and the use of this composition in the treatment of dark circles. Periorbital hyperpigmentation is a condition that does not add any risks to the patient's health state, however, it can cause aesthetic discomforts and appearance of tiredness. Dark circles can be formed due to anatomy or fat accumulation; due to a very thin skin thickness, allowing visualization of subcutaneous vessels; and, furthermore, due to melanin accumulation in the region. Due to this disclosure being a cosmetic composition, of topic non-invasive application, it can be applied daily without the requirement for an aesthetic specialist, besides not being as expensive as the currently known techniques for dark circles treatment. The peptide acts inhibiting melanogenesis.[French]
La divulgation concerne un peptide (Iaká (SEQ ID No1) ayant une action d'éclaircissement pour l'hyperpigmentation périorbitaire, une composition cosmétique ou dermopharmaceutique contenant ce peptide et l'utilisation de cette composition dans le traitement de cernes sombres. L'hyperpigmentation périorbitaire est une affection qui n'ajoute pas de risques à l'état de santé du patient, cependant, elle peut provoquer des désagréments esthétiques et l'apparition de rougeurs. Les cernes peuvent se former en raison de facteurs anatomiques ou d'une accumulation de graisse ; en raison d’une très faible épaisseur de la peau, permettant la visualisation de vaisseaux sous-cutanés ; et, en outre, en raison de l'accumulation de mélanine dans la région. Une composition cosmétique à application non invasive, selon la présente divulgation, peut être appliquée quotidiennement sans exiger un spécialiste en esthétique, en plus de ne pas être aussi coûteuse que les techniques actuellement connues pour le traitement des cernes sombres. Le peptide agit par inhibition de la mélanogenèse.